Skip to main content

Retirement planning: How to adopt FIRE model to retire early, achieve financial security

The Economic Times

ET WEALTH EDITION

Tue, Oct 31, 2023 | 09:30 AM IST

1

Retirement planning: How to adopt FIRE model to retire early, achieve financial securityRetirement planning: How to adopt FIRE model to retire early, achieve financial security

2

Opt for firms with steady capital expenditure: 5 stocks with up to 32% upside potentialOpt for firms with steady capital expenditure: 5 stocks with up to 32% upside potential

3

7 things to do to cope with burnout at work7 things to do to cope with burnout at work

4

Avoid these financial mistakes if you want to retire earlyAvoid these financial mistakes if you want to retire early

This week's money management guide is out!

What It Covers:

  • How to manage your debts?
  • How to achieve early financial security?
Read Latest Edition in PDF »

Slideshows

Best 3-year FD rates for senior citizens: 5 banks that offer up to 8.1% interest
Best 3-year FD rates for senior citizens: 5 banks that offer up to 8.1% interest
Jeevan Pramaan: 4 pre-requisites for generating digital life certificate
Jeevan Pramaan: 4 pre-requisites for generating digital life certificate
You'll spend less with these 7 simple choices
You'll spend less with these 7 simple choices

Financial Calculators

tech
Income Tax
mutual-fund
HomeLoan EMI
economy
NPS
5

Where to invest if you need Rs 40,000 per month during retirementWhere to invest if you need Rs 40,000 per month during retirement

6

Should you invest in the latest, true-to-label balanced hybrid mutual funds?Should you invest in the latest, true-to-label balanced hybrid mutual funds?

7

If in debt, you should not do thisIf in debt, you should not do this

8

Advance tax payment: Who should pay, due dates, how to calculateAdvance tax payment: Who should pay, due dates, how to calculate

9

Ceat stock price up 40.7% in last one year compared to Sensex's 7.6%; should you invest?Ceat stock price up 40.7% in last one year compared to Sensex's 7.6%; should you invest?

10

Edelweiss Mid Cap mutual fund has healthy long-term credentials; should you invest?

11

How to overcome the inertia in investing

12

Financial stability within the country does not mean your investments are immune to global developments, especially in the US

13

Category I Alternative Investment Funds: 5 things to know

More Newsletters
ET More Newsletter

Markets Watch

Round up of stock, currency, bond, money and real estate market

SUBSCRIBE
ET More Newsletter

Daily Newsletter

Special stories that round up the major developments of the day

SUBSCRIBE
ET More Newsletter

ET Mutual Fund

A weekly round-up of the top news and views from the mutual fund industry

SUBSCRIBE
View All Newsletters

Thanks for reading. Follow us on Twitter and Facebook.

* If someone forwarded this to you, subscribe here.

* If you do not want to receive this mailer, please unsubscribe here. To make sure this email is not sent to your "junk/spam" folder, select the email and add the sender to your Address Book.

© 2022 Times Internet Limited.

Comments

Popular posts from this blog

The first drug for a common, deadly liver disease is here – and more are coming

VIEW IN BROWSER | SUBSCRIBE TUE, MAR 19, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good morning!  Millions of Americans with a common and potentially life-threatening form of liver disease will soon have access to the first-ever treatment for the condition.    In a landmark decision on Thursday, the Food and Drug Administration approved Madrigal Pharmaceuticals ' drug " Rezdiffra ," to be used along with diet and exercise. The company expects the medicine to be available next month with a hefty price tag of $47,400 per year before insurance and other rebates.    So, why is this approval so important?    First of all, people suffering from the disease badly need a treatment. Rezdiffra is specifically approved to treat patients with nonalcoholic steatoh

J&J, Merck and Bristol Myers Squibb are in the hot seat

VIEW IN BROWSER | SUBSCRIBE TUE, JAN 30, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good afternoon! This is Annika Kim Constantino, and I cover the biotech and pharmaceutical industry for CNBC.com .    Three names in the industry – Johnson & Johnson, Merck and Bristol Myers Squibb – face a pivotal few weeks ahead.    CEOs from those companies are slated to testify at a Senate hearing on high prescription drug prices in the U.S. on Feb. 8 at 10 a.m. ET, Sen. Bernie Sanders announced Friday.   It took subpoena threats from the senator, but J&J CEO Joaquin Duato and Merck CEO Robert Davis have agreed to testify after both executives declined earlier requests to appear at the Senate HELP committee's hearing. They join Bristol Myers Squibb CEO Chris Boerner, who agr

How competitive can Roche be in the weight loss drug market?

VIEW IN BROWSER | SUBSCRIBE TUE, SEP 17, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon!  Roche is one of several drugmakers hoping to join the booming weight loss drug market, which Novo Nordisk and Eli Lilly are currently dominating. But can the Swiss company develop drugs that can compete with that duopoly?  The answer isn't clear yet.  We need to see more data from longer and larger clinical trials, which will likely take years for Roche to conduct.  But the company last week presented more early-stage data more early-stage data on its experimental obesity injection and pill, which some analysts said raised concerns about how competitive those products can be if they enter the space. Some analysts said the new results showed that both drugs – which Roche acquired through its nearly $3 billion acquisition of Carmot Therapeutics in December – caused a higher rate of side